GlassScriptPhysician profile
Dennis Daniel Dey
NPI 1972546364
$8,309.33
in general payments reported to CMS, 2019-2025
34 companies · $2,046 in 2025
The $2,046 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $276 · 2021: $815 · 2022: $1,727 · 2023: $1,747 · 2024: $1,427 · 2025: $2,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,861 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,860.84 |
| Education | $358.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,132.47 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Lilly USA, LLC | $940.78 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Alexion Pharmaceuticals, INC. | $910.97 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $890.32 | 2021-2025 | Ubrelvy, Qulipta |
| Amneal Pharmaceuticals LLC | $505.28 | 2019-2024 | Rytary |
| Pfizer INC. | $487.60 | 2023-2025 | |
| Celgene Corporation | $468.85 | 2021-2025 | Zeposia |
| Medtronic, INC. | $450.04 | 2021-2025 | Inceptiv, Intellis Adaptivestim, Vectris Surescan |
| Novartis Pharmaceuticals Corporation | $304.77 | 2019-2025 | |
| Eisai INC. | $272.78 | 2023-2025 | |
| Lundbeck LLC | $213.33 | 2024-2025 | Vyepti |
| Argenx US, INC. | $193.10 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $184.70 | 2019-2023 | Austedo, Ajovy |
| Tanabe Pharma America, INC. | $178.87 | 2021-2025 | Radicava |
| Genentech USA, INC. | $164.93 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $156.11 | 2025 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $98.33 | 2022 | |
| Amgen INC. | $93.14 | 2019-2022 | |
| Neurelis, INC. | $89.08 | 2024-2025 | Valtoco |
| Horizon Therapeutics Plc | $81.03 | 2022-2023 | Uplizna |
| Biodelivery Sciences International, INC. | $78.50 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $75.05 | 2023-2025 | Belbuca |
| Insightec,INC | $49.31 | 2023 | Exablate |
| Biohaven Pharmaceuticals, INC. | $48.76 | 2021 | |
| Valinor Pharma, LLC | $46.26 | 2023-2024 | Movantik |
| Tg Therapeutics, INC. | $42.47 | 2023 | |
| Life Molecular Imaging LTD | $28.58 | 2023-2024 | Neuraceq |
| Averitas Pharma INC. | $23.96 | 2024 | Qutenza |
| Curium US LLC | $22.48 | 2024 | Detectnet |
| Genzyme Corporation | $20.89 | 2022 | |
| Acadia Pharmaceuticals INC | $16.32 | 2021 | |
| Avion Pharmaceuticals | $14.07 | 2022 | |
| Currax Pharmaceuticals LLC | $13.70 | 2021 | |
| Redhill Biopharma INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Dey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.